Healthcare Sector
Market Tracker
15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
TransCode Makes Bold Bet On Melanoma Vaccine With Polynoma Buyout
10/08 10:48 am
Benzinga
Read moreUS Stocks Likely To Open Lower After S&P 500's 9-Day Streak: 'Any De-Escalation In Trade Tensions Should Be Positive,' Says Expert
05/05 06:27 am
Benzinga
Read moreWhy Transcode Therapeutics (RNAZ) Stock Is Down 60% - Benzinga
07/23 01:26 pm
Benzinga
Read moreBeat the Market Like Zacks: Goldman Sachs, Micron, Amgen in Focus
06/10 08:07 am
Zacks Investment Research
Read moreNasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
06/10 07:00 am
GlobeNewswire Inc.
Read moreTransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
05/29 09:15 am
GlobeNewswire Inc.
Read moreSuccessful Penny Stocks Trader Tips, 3 To Use
05/12 06:18 am
PennyStocks
Read moreTransCode Therapeutics Reports 2023 Results; Provides Business Update
04/03 09:10 am
GlobeNewswire Inc.
Read moreTransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
03/28 08:30 am
GlobeNewswire Inc.
Read moreTransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
03/11 09:00 am
GlobeNewswire Inc.
Read moreTransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
03/06 05:15 pm
GlobeNewswire Inc.
Read moreNasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
01/31 05:05 pm
GlobeNewswire Inc.
Read moreTransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
01/29 09:30 am
GlobeNewswire Inc.
Read moreTransCode Therapeutics Announces Closing of $7.25 Million Public Offering
01/22 05:45 pm
GlobeNewswire Inc.
Read moreTransCode (RNAZ) Down 50% on Issue of New Common Stock
01/19 02:09 pm
Zacks Investment Research
Read moreTransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
01/18 02:27 pm
GlobeNewswire Inc.
Read moreTransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO
01/12 05:05 pm
GlobeNewswire Inc.
Read moreTransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives
01/04 09:05 am
GlobeNewswire Inc.
Read moreTransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138
12/12 09:30 am
GlobeNewswire Inc.
Read moreTransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
12/04 05:10 pm
GlobeNewswire Inc.
Read moreTransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
11/30 03:53 pm
GlobeNewswire Inc.
Read moreTransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update
11/14 05:30 pm
GlobeNewswire Inc.
Read moreTransCode Therapeutics Withdraws Public Offering
10/30 04:33 pm
GlobeNewswire Inc.
Read moreNasdaq Jumps 100 Points; Amazon Posts Upbeat Earnings
10/27 09:43 am
Benzinga
Read moreNasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to Conditions
10/27 08:00 am
GlobeNewswire Inc.
Read moreTransCode Therapeutics Announces Public Offering of Common Stock
10/26 04:19 pm
GlobeNewswire Inc.
Read moreTransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Lead Therapeutic Candidate, TTX-MC138
10/24 08:00 am
GlobeNewswire Inc.
Read moreTransCode Therapeutics Announces Closing of $8.5 Million Public Offering
09/28 04:02 pm
GlobeNewswire Inc.
Read moreCrude Oil Moves Higher; Cintas Earnings Top Estimates
09/26 12:04 pm
Benzinga
Read moreDow Tumbles 150 Points; US House Prices Rise in July
09/26 09:46 am
Benzinga
Read moreTransCode Therapeutics Announces Pricing of $8 Million Public Offering
09/25 08:01 pm
GlobeNewswire Inc.
Read moreAmazon Invests Up To $4B In ChatGPT Competitor, Hollywood Writers Accept Preliminary Deal, ChatGPT Challenges Siri And Alexa With Introduction Of Verbal Responses: Today's Top Stories
09/25 10:58 am
Benzinga
Read moreU.S. Stocks Open Lower; Chicago Fed Index Falls In August
09/25 09:58 am
Benzinga
Read moreTransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138
09/25 08:30 am
GlobeNewswire Inc.
Read more